BDTX logo

BDTXBlack Diamond Therapeutics Inc

$1.97
$0.12
(5.74%)
Today
Closed $1.97
$0.0268
(1.36%)
After Hours
Updated: 07:51 PM EDT
EarningsAug 6
Mkt Cap$112.88M
Vol1.02M
News
all
press releases
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
Zacks
News Placeholder
More News
News Placeholder
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
Zacks
News Placeholder
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
Zacks
News Placeholder
What's Going On With Black Diamond Therapeutics Stock Tuesday?
Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving averages, and price action.read more...
Benzinga
News Placeholder
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.
Zacks
News Placeholder
BDTX Shares Gain 11% in a Week: Here's What You Should Know
Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and continued progress for lead candidate silevertinib.
Zacks
News Placeholder
Black Diamond Therapeutics (BDTX) to Release Quarterly Earnings on Monday
Black Diamond Therapeutics (NASDAQ:BDTX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-black-diamond-therapeutics-inc-stock...
MarketBeat
News Placeholder
HC Wainwright Issues Positive Forecast for BDTX Earnings
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - HC Wainwright upped their Q1 2026 earnings estimates for shares of Black Diamond Therapeutics in a research note issued on Wednesday...
MarketBeat
News Placeholder
Implied Volatility Surging for Black Diamond Therapeutics Stock Options
Investors need to pay close attention to BDTX stock based on the movements in the options market lately.
Zacks
News Placeholder
Jefferies Financial Group Upgrades Black Diamond Therapeutics (NASDAQ:BDTX) to Strong-Buy
Jefferies Financial Group upgraded shares of Black Diamond Therapeutics to a "strong-buy" rating in a report on Thursday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.